Percutaneous Absorption and Model Membrane Variations of Melatonin in Aqueous-based Propylene Glycol and 2-Hydroxypropyl-$\beta$-cyclodextrin Vehicles

  • Lee, Beom-Jin (Biological rhythm and controlled release lab., College of Pharmacy, Kangwon National University) ;
  • Cui, Jing-Hao (Biological rhythm and controlled release lab., college of Pharmacy, Kangwon National University) ;
  • Keith A. Parrott (Department of Pharmaceutics, College of Pharmacy, Oregon State University) ;
  • James W.Ayres (Department of Pharmaceutics, College of Pharmacy, Oregon State University) ;
  • Robert L.Sack (Department of Psychiatry, School of medicine, Oregon Health Science University)
  • Published : 1998.10.01

Abstract

Percutaneous absorption and model membrane variations of melationin (MT) in aqueous-based propylene glycol and $2-hydroxypropyl-{\beta}-cyclodextrin $vehicles were investigatted. the excised hairless mouse skin (HMS) and two synthetic ethylene vinyl acetate (EVA) and microporous polyethylene (MPE) were selected as a model membrane. the solubility of MT was determined by phase equilibrium study. the vertical $Franz{\circledR}$ type cell was used for diffusion study. The concentration of MT was determined using reverse phse HPLC system. The MT solubility was the highest in a mixture of PG and $2-HP{\beta}CD$. The percutaneous absorption of MT through excised HMS increased as the solubility increased. However, the permeability coefficient decreased and then slightly increased in mixture of PG and $2-HP{\beta}CD$. On the other hand, both flux and permeability coefficient through EVA membrane decreased as the solubility increased. No MT was detected over 12 h after starting diffusion through MPE membrane. The flux of MT was dependent on the type of membrane selected. Flux of MT was greatest in excised HMS followed by EBA and MPE membrane. Flux of MT through EVA membrane was 5-20 times lower when compared to excised HMS. Interestingly, volumes of donor phase when MPE membrane was used, significantly increased during the study period. the HMS might be applicable to expect plasma concentration of MT in human subjects based on flux and pharmacokinetic parameters as studied previously. the current studies may be applied to deliver MT transdermally using aqueous-based vehicles and to fabricate MT dosage forms.

Keywords

References

  1. Proceedings from the congress on pineal gland Plasma melatonin(M)and Sulfaoxymelatonin(aMT6s)kinetics after transmucosal administration to humans. Melatonin and the pineal glanf-from basic science to clinical application Benus;L.;Brun;J.;Claustrat;B.;Ducloux;N.;Geoffriau;M.;Horriere;F.;Karsenty;H.;Lagain;D.
  2. Pharm. Res. v.13 Iontophoretic delivery of hydrocortosone from cyclodextrin solutions Chang;S.;Banga;A.K.
  3. Lancet v.346 Improvement of sleep quality in elderly people by controlled-release melatonin Garfinkel;D.;Laudon;M.Dof;D.;Zisapel;N.
  4. Transdermal drug delivery. Development issues and research initatives. Hadgraft;J.;Guy;R.H.
  5. Sleep v.18 Melatonin replacement therapy of elderly insomniacs Haimov;I.;Lavie;P.;Laudon;M.;Herer;P.;Vigder;C.;Zisapel;N.
  6. Drug Dev. Ind. Pharm. v.21 Development of a ransfermal delovert device for melatonin in vitro study Konsil;J.;Parrott;K.A.;Ayres;J.W.;Sack;R.L.
  7. Transdermal delivery of drugs. Vol.Ⅰ;Ⅱ;&Ⅲ Kydonieus;A.K.;Berner B.
  8. J. Microencapsulation Preparation and characterization of melatonin-loaded steary alcohol microspheres Lee;B.J.;Choe;J.S.;Kim;C.K
  9. Arch. Pharm. Res. v.20 Solubility and stability of melatonin in propylene glycol and 2-hydroxpropyl-β-cyclodextrin Lee;B.J.;Choi;H.G.;Kim;C.K;Parrott;K.A.;Ayres;J.W.;Sack;R.L.
  10. Int. J. Pharm. v.144 Oral controlled release of melatonin using polymer-reinforced and coated alginate beads Lee;B.J.;Min;G.H.
  11. Res. comm. Mol. Pathol. & Pharmacol v.85 Preliminary evaluation of transfermal delivery of melatonin in human subjects Lee;B.J.;Parrott;K.A.;Ayres;J.W.;Sack;R.L.
  12. Int. J. Pharm. v.124 Design and evaluation of an oral controlled realese delivery system for melatonin in human subjects Lee;B.J.;Parrott;K.A.;Ayres;J.W.;Sack;R.L.
  13. Drug. Dev. Ind. Pharm. v.22 Development and characterization of an oral controlled release delivery system for melatonin Lee;B.J.;Parrott;K.A.;Ayres;J.W.;Sack;R.L.
  14. Acta Pharm. Nordica Effects of 2-hydroxypropyl-β-cyclodextrin on the aqueous solubility of grugs and transfermal delivery of 17β-estradol Loftsson;T.;Border;N.
  15. J. Pharm. Sci. v.85 Controlled of pressues-sensitive adhesives for matrix patch design Roy;S.D.;Gutierrez;M.;Flynn;G.L.;Cleary;G.W.
  16. Pharm. Res. v.9 Cyclodextrins as nasal absorptin promotors of insulin Shao;Z.;Krishnamoorthy;R.;Mitra;A.K.
  17. Ann. NY. Acad. Sci. v.453 Daily and annual rhythms in human melatonin secrerion:role in puberty Waldhauser;F.;Dietzel;M.